In order to protect patients, the EU Falsified Medicines Directive (FMD) introduces harmonized measures to prevent falsified medicines from entering the legal supply chain of the European market. An end-to-end verification system is being implemented through a European-wide system (European Medicines Verification System – EMVS) and the implementation of safety features in order to verify the authenticity of the affected medicines before being dispensed to the public. EMVO is strongly committed to guarantee that the implementation of the Falsified Medicine Directive is a secure and beneficial solution for all supply chain partners ensuring as overarching goal patients’ safety.
The European Medicines Verification Organisation (EMVO) was created in 2015 as a joint initiative of EU supply chain stakeholders, representing manufacturers (EAEPC, EFPIA, Medicines for Europe,), wholesalers (GIRP), community pharmacists (PGEU) and hospitals (EAHP, HOPE) and is responsible for advancing the formation of the European Medicines Verification System (EMVS) in accordance with the EU’s Falsified Medicines Directive (FMD) and the Delegated Regulation (DR). It ensures the implementation of a functioning, secure, interoperable and cost-effective system across Europe, to ensure patient health and safety.